Regulators and Payors
Payors invest significant sums in the treatment of wet AMD in all developed countries. This investment is clearly warranted and delivers a well documented ROI.
However there remains scope to significantly improve these societal benefits through more finely tuned treatment protocols, as well as improved adherence and persistence.
Macuject is a powerful tool for applying the protocols and approaches that deliver the greatest real-world benefit.